Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

980

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19 Immunization
Influenza Immunization

Interventions

BIOLOGICAL: IIV-HD
BIOLOGICAL: rC19 (dose 1)
BIOLOGICAL: IIV-HD + rC19 (dose 1)
BIOLOGICAL: IIV-HD + rC19 (dose 2)
BIOLOGICAL: IIV-HD + rC19 (dose 3)
BIOLOGICAL: IIV-HD + rC19 (dose 4)
OTHER: Placebo (0.9% NaCl)

Sponsor

Sanofi